Corona crisis has limited impact on infant participation in National Immunisation Programme Nearly all infants in the Netherlands are still participating in the National Immunisation Programme.
Initial results on how COVID-19 spreads within Dutch families The novel coronavirus is primarily spread amongst adults who are about the same age. Within families, the virus is mainly transmitted from adults to children.
Screening for chronic Q-fever is only cost-effective for specific groups RIVM has investigated for which groups screening for chronic Q-fever might be cost-effective.
Pneumococcal disease in the elderly The Health Council of the Netherlands is preparing an advice on pneumococcal vaccination for the elderly on request of the Ministry of Health, Welfare and Sport.
Statement on health care spending Down syndrome Recently a tweet containing a video from a Dutch tv-show about Down syndrome caused a lot of turmoil on Twitter.
Temporary dermal fillers prove harmless RIVM has conducted a market surveillance study of 26 so-called non-permanent fillers. All 26 products proved to be harmless.
Slight increase of the number of tuberculosis patients in 2016 For the second consecutive year, the number of tuberculosis (TB) patients in the Netherlands increased.
Promising biobased alternatives to controversial polar aprotic solvents There are a number of promising biobased alternatives to controversial polar aprotic solvents, as revealed in a report from Wageningen Food & Biobased Research commissioned by RIVM .
Lyme disease costs EUR 20 million annually The societal costs of Lyme disease have been determined for the Netherlands for the first time. The disease appears to cost nearly EUR 20 million each year.
Slight increase of ammonia emissions In 2015 slightly more ammonia was emitted in the Netherlands than in 2014 and the ceiling set by the European Union was met (128 kilotons).